Business Model Breakdown
How Arrowhead Pharmaceuticals Inc Makes Money
ARWR
Market Cap
$9.7B
Annual Revenue
$545M
Profit Margin
18.5%
Employees
711
The Short Version
Arrowhead Pharmaceuticals is a biotechnology company focused on developing a new class of medicines called RNA interference (RNAi) therapeutics. These medicines work by 'silencing' specific genes that cause diseases, particularly those involving the liver, heart, and lungs. The company discovers, develops, and seeks regulatory approval for these drugs, then sells them either directly or through partnerships with larger pharmaceutical companies, generating revenue from product sales, milestone payments, and potential royalties. Their first approved product, Redemplo, treats a rare genetic condition, and their main growth driver, plozasiran, is advancing towards approval for broader cholesterol-related disorders.
Where the Revenue Comes From
Product sales (e.g., Redemplo) (~70-80% of current revenue, growing)
Milestone payments from strategic collaborations (~10-20% of current revenue, variable)
Potential royalties from partnered products (~5-10% of future revenue)
Who buys: Patients suffering from genetic and chronic diseases (e.g., hypertriglyceridemia, Familial Chylomicronemia Syndrome), prescribed by healthcare professionals. Also, strategic pharmaceutical partners who license their technology or pipeline assets.
Why It Works (Competitive Advantages)
- ✔Proprietary TRiM RNAi delivery platform offering enhanced targeting and reduced off-target effects.
- ✔Extensive patent portfolio and intellectual property in the RNAi space.
- ✔First-mover advantage in certain niche indications like Familial Chylomicronemia Syndrome (FCS).
Economic Moat: Narrow (Intangible Assets/IP (Proprietary TRiM platform, specific RNAi drug sequences, and broad patent portfolio), Switching Costs (Potential for physicians and patients to switch to established, effective RNAi therapies once integrated into treatment protocols))
What Our Analysis Says
DVR Score as of April 21, 2026
Arrowhead Pharmaceuticals continues to demonstrate strong 10x growth potential within 3-5 years. The Q1 2026 financials (fiscal quarter ended Dec 31, 2025) showcased a significant revenue beat of $264.0M, driven by the successful commercial launch of Redemplo, and a positive net margin of 18.54%. Critically, the recently announced two-year efficacy data for plozasiran, showing an 83% triglyceride reduction and confirming an sNDA submission by year-end 2026, significantly de-risks a major pipeline asset. While the company anticipates negative full-year EPS due to continued R&D investment in its robust RNAi pipeline, its strong net cash position of $798M provides ample runway. The clear strategic vision, expanding competitive moat through its TRiM platform and IP, and consistent clinical progress, along with positive analyst sentiment, underscore its potential for substantial long-term growth and market disruption in the cardiometabolic space. The valuation remains at a premium, reflecting high growth expectations, but key catalysts are on the horizon. The score reflects a slight positive reinforcement from the strong plozasiran data.